Celyad Oncology SA (FRA:1C0)
Germany · Delayed Price · Currency is EUR 0.1785
+0.0010 (0.56%)
Last updated: Dec 1, 2025, 8:35 AM CET
Celyad Oncology Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '25 Jun 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.19 | 0.19 | 0.1 | - | - | 0.01 | Upgrade | |
Revenue Growth (YoY) | 158.33% | 82.35% | - | - | - | -16.67% | Upgrade |
Cost of Revenue | 0.01 | 0.01 | 0.07 | - | - | - | Upgrade |
Gross Profit | 0.18 | 0.17 | 0.03 | - | - | 0.01 | Upgrade |
Selling, General & Admin | 3.14 | 3.2 | 6.25 | 10.56 | 10 | 9.39 | Upgrade |
Research & Development | 3.78 | 3.24 | 4.38 | 18.91 | 20.69 | 21.44 | Upgrade |
Other Operating Expenses | -0.3 | -0.39 | -1.05 | -4.03 | -3.44 | -4.59 | Upgrade |
Operating Expenses | 6.62 | 6.04 | 9.58 | 25.45 | 27.24 | 26.25 | Upgrade |
Operating Income | -6.44 | -5.87 | -9.54 | -25.45 | -27.24 | -26.24 | Upgrade |
Interest Expense | -0.1 | -0.12 | -0.08 | -0.2 | -0.26 | -0.3 | Upgrade |
Interest & Investment Income | 0.08 | 0.15 | 0.03 | 0.01 | 0.03 | 0.05 | Upgrade |
Currency Exchange Gain (Loss) | - | - | - | 0.17 | 0.01 | -0.14 | Upgrade |
Other Non Operating Income (Expenses) | -0 | - | - | -0 | 0.11 | 0.17 | Upgrade |
EBT Excluding Unusual Items | -6.47 | -5.84 | -9.6 | -25.46 | -27.35 | -26.46 | Upgrade |
Impairment of Goodwill | - | - | - | -0.64 | - | - | Upgrade |
Gain (Loss) on Sale of Assets | 0.01 | 0.01 | 1.09 | 5 | -0 | 0.03 | Upgrade |
Asset Writedown | - | - | - | -34.44 | - | - | Upgrade |
Other Unusual Items | - | - | - | 14.68 | 0.85 | 9.23 | Upgrade |
Pretax Income | -6.46 | -5.82 | -8.51 | -40.87 | -26.5 | -17.2 | Upgrade |
Income Tax Expense | - | - | -0.06 | 0.07 | 0.01 | - | Upgrade |
Net Income | -6.46 | -5.82 | -8.45 | -40.94 | -26.51 | -17.2 | Upgrade |
Net Income to Common | -6.46 | -5.82 | -8.45 | -40.94 | -26.51 | -17.2 | Upgrade |
Shares Outstanding (Basic) | 41 | 41 | 26 | 23 | 16 | 14 | Upgrade |
Shares Outstanding (Diluted) | 41 | 41 | 26 | 23 | 16 | 14 | Upgrade |
Shares Change (YoY) | 17.90% | 61.06% | 13.84% | 44.80% | 11.92% | 11.33% | Upgrade |
EPS (Basic) | -0.16 | -0.14 | -0.33 | -1.81 | -1.70 | -1.23 | Upgrade |
EPS (Diluted) | -0.16 | -0.14 | -0.33 | -1.81 | -1.70 | -1.23 | Upgrade |
Free Cash Flow | -6.12 | -5.68 | -16.1 | -28.13 | -26.97 | -27.82 | Upgrade |
Free Cash Flow Per Share | -0.15 | -0.14 | -0.63 | -1.25 | -1.73 | -2.00 | Upgrade |
Gross Margin | 94.09% | 93.55% | 32.35% | - | - | 100.00% | Upgrade |
Operating Margin | -3462.37% | -3155.91% | -9356.86% | - | - | -524800.00% | Upgrade |
Profit Margin | -3470.43% | -3131.18% | -8282.35% | - | - | -344080.00% | Upgrade |
Free Cash Flow Margin | -3291.93% | -3053.76% | -15785.29% | - | - | -556300.00% | Upgrade |
EBITDA | -6.28 | -5.69 | -9.04 | -24.74 | -26.68 | -24.41 | Upgrade |
D&A For EBITDA | 0.16 | 0.18 | 0.51 | 0.71 | 0.56 | 1.83 | Upgrade |
EBIT | -6.44 | -5.87 | -9.54 | -25.45 | -27.24 | -26.24 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.